USFDA grants appeal for Ardelyx's XPHOZAH

Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism

AIIMS organises consultation on ‘C2IQ’

For anaemia control in children (0-19 years) & resolves for Call to Action in this direction

WBF signs MOU with Sharda University to help advance biocontrol sector

LG Chem inks deal with Innovent Biologics for gout treatment candidate

LG Chem will receive totaling up to $95.5 million for the China rights

PM lays foundation stone for National Institute for One Health in Nagpur

The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents

GSK’s new data underscore important responses with momelotinib for myelofibrosis patients

48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response

Apollo Conclave 2022 highlights role of research in driving better clinical outcomes

The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival

EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints

Merck to acquire Imago BioSciences for $1.35 bn

Acquisition expands Merck’s growing hematology portfolio